Cargando…

Predicting progression of Alzheimer's disease

INTRODUCTION: Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate to see whether it predicted performance on cognition, function and behavi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doody, Rachelle S, Pavlik, Valory, Massman, Paul, Rountree, Susan, Darby, Eveleen, Chan, Wenyaw
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874261/ https://www.ncbi.nlm.nih.gov/pubmed/20178566 http://dx.doi.org/10.1186/alzrt25

Ejemplares similares

Correction: Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Factors that influence survival in a probable Alzheimer disease cohort
por: Rountree, Susan D, et al.
Publicado: (2012)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment
por: Pavlik, Valory N, et al.
Publicado: (2011)

Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease
por: Liang, Fu-Wen, et al.
Publicado: (2016)

Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer's Disease: Comparison of Efficacy and Effectiveness Studies
por: Atri, Alireza, et al.
Publicado: (2012)

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
por: Pavlik, Valory N., et al.
Publicado: (2022)

Alzheimer’s disease progression by geographical region in a clinical trial setting
por: Henley, David B, et al.
Publicado: (2015)

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
por: Spiegel, René, et al.
Publicado: (2013)

Associations Between Vascular Diseases and Alzheimer’s Disease or Related Dementias in a Large Cohort of Men and Women with Colorectal Cancer
por: Du, Xianglin L., et al.
Publicado: (2022)

Risk of Developing Alzheimer’s Disease and Related Dementias in Association with Cardiovascular Disease, Stroke, Hypertension, and Diabetes in a Large Cohort of Women with Breast Cancer and with up to 26 Years of Follow-Up
por: Du, Xianglin L., et al.
Publicado: (2022)

The influence of common method bias on the relationship of the socio-ecological model in predicting physical activity behavior
por: Wingate, Savanna, et al.
Publicado: (2018)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

CHRFAM7A: A human specific fusion gene, accounts for the translational gap for cholinergic strategies in Alzheimer's disease
por: Szigeti, Kinga, et al.
Publicado: (2020)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI
por: O'Bryant, Sid E., et al.
Publicado: (2011)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease
por: Johnson, Piers, et al.
Publicado: (2014)

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2015)

Predicting Progression of Alzheimer’s Disease Using Ordinal Regression
por: Doyle, Orla M., et al.
Publicado: (2014)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019)

Adherence to diabetes self-care behaviors in English- and Spanish-speaking Hispanic men
por: Rustveld, Luis O, et al.
Publicado: (2009)

Should EOAD patients be included in clinical trials?
por: Szigeti, Kinga, et al.
Publicado: (2011)

Should persons with autosomal dominant AD be included in clinical trials? Authors' response
por: Szigeti, Kinga, et al.
Publicado: (2011)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Randomized Controlled Trial Considering Varied Exercises for Reducing Proactive Memory Interference
por: Frith, Emily, et al.
Publicado: (2018)

Safe sex self-efficacy and safe sex practice in a Southern United States College
por: Addoh, Ovuokerie, et al.
Publicado: (2017)

Validation of the Alzheimer’s disease-resemblance atrophy index in classifying and predicting progression in Alzheimer’s disease
por: He, Qiling, et al.
Publicado: (2022)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression
por: Chen, Xueqi, et al.
Publicado: (2016)

Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer’s Disease
por: Cova, Ilaria, et al.
Publicado: (2016)

Predictive Modeling of the Progression of Alzheimer’s Disease with Recurrent Neural Networks
por: Wang, Tingyan, et al.
Publicado: (2018)

Posterior Cingulate Cortex Network Predicts Alzheimer's Disease Progression
por: Lee, Pei-Lin, et al.
Publicado: (2020)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy
por: Chen, Dalbert J., et al.
Publicado: (2021)

Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes
por: Haaksma, Miriam L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_47ffhlb4jlnre6p97cfq6bprd7